Skip to content

Heart Failure in Norway: Clinical Characteristics, Mortality and Health Care Resource Use

Heart Failure in Norway: Combining Artificial Intelligence and a Database of 15000 Patients to Understand Clinical Characteristics, Mortality and Health Care Resource Use

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04398563
Enrollment
14998
Registered
2020-05-21
Start date
2020-01-20
Completion date
2023-12-31
Last updated
2020-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction

Brief summary

The prevalence of Heart failure above 70 years of age is 10% and 5 year mortality rate above 60%, higher than for cancer. The readmission rate first after hospitalisation is 44% despite the availability of life prolonging and life quality enhancing treatment. There is a lack of resources for adequate diagnostic workup necessary for implementing evidence-based treatment. This projects aims at assessing the impact of guidelines based diagnostic workup and guidelines based treatment of heart failure on mortality and readmission rates. As the symptoms defining the degree of heart failure and the discharge medication only is available in the electronic patient files, artificial intelligence is used to retrieve this information to assess if treatment is according to guidelines. The project is using first a rule based text processing approach using IBM Watson, then advancing to a machine learning approach using readmission and mortality as endpoints. The project has access to digitally stored echocardiographic measurements as well as digital ECG's and lab data on 15 000 patients admitted with a diagnosis of Heart failure. If the retrieval of symptoms and function by artificial intelligence is successful, the next step is to assess if those benefitting the most from echocardiography can be identified using information from the ECG's, lab data or symptoms and functional capacity as described in the Electronic Health Records.

Interventions

None listed

Sponsors

Novartis
CollaboratorINDUSTRY
University Hospital, Akershus
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Diagnosis with ICD10 codes as follows; I50.\*, I42.3, I11.\* and COPD J44.\* from 2007 through 2019. In addition all subjects with NT-proBNP above age specific normal range in same period.

Exclusion criteria

none

Design outcomes

Primary

MeasureTime frameDescription
ReadmissionChange over 12 years30 days and 1 year readmission rate
MortalityChange over 12 years1 year mortality rate after first diagnosis of heart failure

Secondary

MeasureTime frameDescription
Diagnostic work up according to guidelinesWithin 6 months before or after first diagnosisProportion with echocardiography and other necessary investigations
Treatment according to guidelineswithin first year after first diagnosisProportion treated according to guidelines

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026